Trial Profile
Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Enoxaparin Sodium (RP54563) 20mg qd and 20mg Bid for 14 Days in Patients With Total Hip Replacement.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jul 2009
Price :
$35
*
At a glance
- Drugs Enoxaparin sodium (Primary)
- Indications Thromboembolism
- Focus Therapeutic Use
- Sponsors Sanofi
- 19 Jan 2007 Status changed from recruiting
- 22 Sep 2006 New trial record.